article · Journal of Medicine and Health Research
Breast Cancer Type 1 Susceptibility Protein, or BRCA1, is a vital tumour suppressor involved in DNA repair, chromatin remodelling, and transcription regulation. Mutations in BRCA1 significantly elevate the risk of breast and ovarian cancers, yet targeting it therapeutically remains difficult. Using the STRING database alongside K-means clustering and Reactome pathway analysis, this study mapped a high-confidence protein interaction network for BRCA1. The findings reveal that BRCA1 operates at the crossroads of endocrine, hormonal, and metabolic regulation. Key interactors were identified, especially within the PI3K-AKT signalling pathway, presenting potential novel targets. These functional insights suggest opportunities for integrated hormonal and metabolic therapies to treat BRCA1-associated cancers, potentially aiding the creation of better diagnostic and therapeutic strategies for related malignancies.
BRCA1 mutations significantly increase the risk of aggressive breast and ovarian cancers, but directly targeting this protein with drugs has proved difficult. By mapping how BRCA1 interacts with other cellular components, researchers can uncover indirect targets, such as the PI3K-AKT pathway, offering new directions for designing treatments and diagnostics for patients carrying these genetic risks.
This computational network analysis represents early-stage research that identifies candidate drug targets, particularly within the PI3K-AKT pathway, for BRCA1-related malignancies. Pharmaceutical and biotechnology companies developing targeted oncology treatments could use these interaction maps to inform drug discovery and combined hormonal-metabolic therapies. However, moving from these bioinformatic findings to actual clinical treatments remains distant and will require extensive laboratory and clinical validation.
AI-generated from the published abstract. Always read the original work before citing.
Background: Breast Cancer Type 1 Susceptibility Protein (BRCA1) is an important tumour suppressor gene that plays a crucial role in preserving genomic stability through its involvement in DNA repair, chromatin remodelling, and transcription regulation. The risk of some diseases, such as breast and ovarian cancer, increases significantly when the BRCA1 gene is mutated. However, targeting the BRCA1 gene in cancer therapy has remained a significant challenge for scientists. Objective: The study aims to explore the protein interaction network of BRCA1 to elucidate its functional associations and regulatory mechanisms, identify previously unrecognised therapeutic targets, and investigate the effect of PI3K-AKT inhibition on BRCA1. Methods: The BRCA1 interaction network was constructed using the STRING database (v12.0) at a high-confidence interaction score (0.900). Clusters of proteins were obtained through K-means, and the main interactors were grouped into three levels by carrying out a thorough analysis through the Reactome pathway. Some common interactors were identified through frequency analysis. In order to uncover the biological processes related to the BRCA1 network, pathway enrichment was subsequently conducted. Results and Discussion: This study elucidates the complex and highly regulated protein interaction network of BRCA1, revealing its pivotal role in multiple cellular pathways. The analysis identified key interactors, particularly within the PI3K-AKT signaling pathway, that may serve as promising therapeutic targets. BRCA1 was also found to function at the intersection of endocrine, hormonal, and metabolic regulation, underscoring its importance in maintaining tissue homeostasis. These findings highlight BRCA1’s potential as a target for integrated hormonal and metabolic therapies in BRCA1-associated cancers. Overall, this study provides insights that could advance the development of more effective diagnostic and therapeutic strategies to improve outcomes for individuals with BRCA-related malignancies.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.56557/jomahr/2025/v10i29935
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
